A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC

  • STATUS
    Recruiting
  • End date
    Oct 25, 2023
  • participants needed
    216
  • sponsor
    Pfizer
Updated on 9 June 2021

Summary

The current study will compare the efficacy, safety, pharmacokinetics and immunogenicity of PF-06439535 (CN) in combination with paclitaxel and carboplatin versus bevacizimab sourced from the European Union (bevacizumab-EU) with paclitaxel and carboplatin in Chinese participants with advanced non-squamous NSCLC in the first-line treatment setting.

Details
Condition Advanced Non-squamous NSCLC, Advanced Non-squamous NSCLC, Advanced Non-squamous NSCLC, Advanced Non-squamous NSCLC, Advanced Non-squamous NSCLC, Advanced Non-squamous NSCLC, Advanced Non-squamous NSCLC, Advanced Non-squamous NSCLC, Advanced Non-squamous NSCLC
Treatment carboplatin, Paclitaxel, Bevacizumab-EU, PF-06439535 (CN)
Clinical Study IdentifierNCT04325698
SponsorPfizer
Last Modified on9 June 2021

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note